Breaking News
Close
0

UCB SA (UCB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
82.74 +0.96    +1.17%
04/07 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  BE0003739530 
S/N:  852738
  • Volume: 95
  • Bid/Ask: 82.72 / 82.74
  • Day's Range: 82.74 - 83.30
UCB 82.74 +0.96 +1.17%
IndustryPharmaceuticals
SectorHealthcare
Employees

8284

Equity Type

ORD

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Contact Information

Phone 32 2 559 99 99
Fax 32 2 559 99 00

Top Executives

Name Age Since Title
Guy Keutgen - 1990 Honorary Director
Mark Eyskens - 2005 Honorary Chairman
Norman J. Ornstein 74 2008 Honorary Director
Karel Boone 79 2000 Honorary Chairman
Arnoud de Pret Roose de Calesberg 78 2005 Honorary Director
Jonathan M. Peacock 64 2021 Independent Director
Charles-Antoine Emmanuel T. Janssen 51 2012 Director
Gaëtan van de Werve - 2006 Honorary Director
Albrecht De Graeve 67 2010 Independent Director
Cyril Janssen 51 2015 Director
Dame Kay Davies 71 2014 Independent Director
Stefan Oschmann 65 2021 Independent Chairman of the Board
Jean-Louis Vanherweghem - - Honorary Director
Jean-Pierre Kinet 69 2008 Honorary Director
Daniel Janssen 86 - Honorary Deputy Chairman
Jonkheer Cédric van Rijckevorsel 52 2014 Director
Alice Dautry 72 2015 Honorary Director
Prince Lorenz - 2001 Honorary Director
Peter J. Fellner 79 2005 Honorary Director
Alan John Blinken - - Honorary Director
Thomas Fulton Wilson McKillop 79 2009 Honorary Director
Fiona du Monceau 44 2021 Vice-Chair of the Board
Frederic Roch Doliveux 66 2005 Honorary Director
Ulf Arne Wiinberg 64 2016 Independent Director
Viviane Monges 59 2017 Independent Director
Pierre L. Gurdjian 61 2016 Independent Director
Gerhard N. Mayr 76 2005 Honorary Chairman
Diégo du Monceau de Bergendal 72 1984 Honorary Chairman
Georges Jacobs de Hagen 82 2005 Honorary Chairman
Jean-Christophe Tellier 63 2014 CEO & Executive Director
Jean van Rijckevorsel - 1992 Honorary Director
Jan Berger 65 2019 Independent Director
Susan Gasser 67 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

UCB Comments

Write your thoughts about UCB SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalised Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email